Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.
Hosted on MSN5d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
$SLDB insiders have traded $SLDB stock on the open market 17 times in the past 6 months. Of those trades, 2 have been purchases and 15 have been sales. Here’s a ...
Truist Financial analyst Joon Lee maintained a Buy rating on Solid Biosciences (SLDB – Research Report) today. The company’s shares closed ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback